Adults — Age 18 Years or Older

Treatment of Synovial Sarcoma in Adults (Age 18 Years or Older)

Synovial sarcoma (SS) is a soft tissue malignancy that affects patients across all adult age groups. For adults aged 18 years or older with advanced or metastatic disease, a structured systemic treatment approach is used. Five-year survival rates in adults with SS have plateaued since the 1980s with no advances in treatment efficacy, underscoring the importance of following an evidence-based protocol.

Clinical Scenario

This protocol is for adult patients — those aged 18 years or older — with synovial sarcoma requiring systemic treatment for advanced or metastatic disease.

Treatment Approach

Second-line systemic therapy options exist for adults with advanced or metastatic synovial sarcoma — the full protocol specifies which agents apply and the criteria for selecting among them.

Complete regimen details, sequencing, and clinical decision criteria are in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.esmoop.2023.101618

Five-year survival rates in adults with SS have plateaued since the 1980s with no advances in treatment efficacy.
For example, in patients treated with ifosfamide combination therapy, high-dose single-agent ifosfamide infusions over 4-5 or 14 days can be administered.
In advanced SS treated with trabectedin, median PFS and OS were 5.6 and 14.3 months, respectively.
Another retrospective study assessing adult patients 24 years of age with refractory STS showed that dacarbazine as a second-line treatment achieved no CRs and a median PFS of 2 months.
Pazopanib is also approved for the treatment of adult advanced STS from the second line.

View source ↗